 |
      
|
|
|
|
|
|||||
|
|
October 5, 2005
Neurochem receives third positive recommendation from Independent Safety Review Board to continue
Phase III clinical trial for Alzhemed™ About Alzhemed™
Alzhemed™ has entered into a multicenter, randomized, double-blind, placebo-controlled, three-armed, parallel-design
Phase III clinical trial; 68 clinical centers have been enrolled in North America. A total of 1,052 patients have been
randomized to receive study medication over a period of 18 months. The Company also launched its Phase III clinical
trial in Europe in September 2005. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The
Company's pipeline of proprietary, disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex™) is designated as an orphan drug, a Fast Track product candidate and
is also part of an FDA Continuous Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex™ for the treatment of AA Amyloidosis was concluded in April 2005. The Company is in the process of
submitting a New Drug Application (NDA) for Fibrillex™ that the FDA has agreed to file and review.
3-amino-1-propanesulfonic acid (3APS; Alzhemed™), for the treatment of Alzheimer's disease, is in a North
American as well as European Phase III clinical trial and 3APS (Cerebril™), for the prevention of Hemorrhagic Stroke
caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are independently verifiable
at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which
are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in
which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation, as well as other risks disclosed in public filings of Neurochem. Consequently, actual
future results may differ materially from the anticipated results expressed in the forward-looking statements. The
reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for
further risk factors that might affect the Company and its business.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
